The three-fold higher cumulative dose administered to DTC/+T2DM patients than those with DTC/−T2DM could be due, in addition, to metformin’s effect on decreasing NIS and thyroid 131I uptake, and to complex mechanisms, including neutrophil-mediated radiotherapy resistance processes. The gene discussed is SLC5A5; the disease is type 2 diabetes mellitus.